5 completed, 5 terminated, 2 withdrawn. 6 Phase 1, 5 Phase 2, 4 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 2, Terminated 2, Withdrawn 2 |
| Phase 2 | 5 | Completed 3, Terminated 2 |
| Phase 3 | 4 | Terminated 3, Completed 1 |
| Not applicable | 1 | Completed 1 |
Follow AlloVir: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation Posoleucel, Placebo - Adenovirus Infection | Phase 3 | Terminated | AlloVir | 57 | 2022-04-26 | 2024-05-08 |
| Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Posoleucel (ALVR105), Placebo - Adenovirus Infection, BK Virus Infection | Phase 2 / Phase 3 | Terminated | AlloVir | 451 | 2022-03-24 | 2024-05-16 |
| Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant ALVR106, Placebo - Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection | Phase 1 / Phase 2 | Terminated | AlloVir | 17 | 2022-03-21 | 2024-06-06 |
| Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia Posoleucel (formerly known as ALVR105) cells, Placebo (visually identical to Posoleucel) - BK Virus Nephropathy, BK Virus Infection | Phase 2 | Completed | AlloVir | 61 | 2021-03-22 | 2024-05-16 |
| Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC) Posoleucel (ALVR105), Placebo - BK Virus Infection, Hemorrhagic Cystitis | Phase 3 | Terminated | AlloVir | 97 | 2021-03-18 | 2024-05-14 |
| Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Posoleucel (ALVR105) - Adenovirus Infection, BK Virus Infection | Phase 2 / Phase 3 | Completed | AlloVir | 26 | 2021-01-15 | 2024-05-09 |
| Anti-SARS Cov-2 T Cell Infusions for COVID 19 Dose Finding Phase (MTD), Partially HLA-matched SARS-CoVSTs, Routine care (no SARS-CoVSTs) - SARS-CoV 2, Viral Infection | Phase 1 | Terminated | Baylor College of Medicine | 4 | 2020-11-04 | 2022-12-19 |
| Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B) Viralym-B - BK Virus Infection | Phase 1 | Withdrawn | AlloVir | 2018-03-01 | 2018-04-09 | |
| Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A) Viralym-A - Adenovirus Infection | Phase 1 | Withdrawn | AlloVir | 2017-12-07 | 2018-07-23 | |
| Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C) Viralym-C - CMV Infections | Phase 1 | Completed | AlloVir | 10 | 2015-09-01 | 2018-12-26 |
| Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant Multivirus Specific T cells - Infection | Not applicable | Completed | AlloVir | 82 | 2014-06-01 | 2021-07-20 |
| ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3 - Viral Infection | Phase 1 / Phase 2 | Completed | AlloVir | 21 | 2012-09-01 | 2019-05-30 |
Adenoviridae Infections (6) · Cytomegalovirus Infections (4) · Epstein-Barr Virus Infections (4) · Virus Diseases (4) · Infections (2) · COVID-19 (1) · Cystitis, Hemorrhagic (1) · Paramyxoviridae Infections (1) · Respiratory Tract Infections (1)
Cell Count (1) · Maximum Tolerated Dose (1)
United States (12) · Italy (3) · Spain (3) · United Kingdom (3) · Canada (2) · France (2) · South Korea (2) · Sweden (2) · Australia (1) · Belgium (1) · Turkey (Türkiye) (1)
Bilal Omer, MD (3) · Swati Naik, MD (3) · Carlos A Ramos, MD (1) · Helen Heslop, MD (1) · Premal Lulla (1)
PMID 38597860, PMID 24964991, PMID 36373249, PMID 36628536, PMID 37323051, PMID 38593233, PMID 39382091